Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples

Reuters04-09 20:09

Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples

Seer Proteograph Product Suite selected to profile plasma proteome in 10,000 PRECISE-SG100K participants under collaboration with Precision Health Research, Singapore.
Project combines Proteograph data with Thermo Fisher Olink Reveal and Orbitrap Astral outputs from same samples to expand proteomic readouts.
Seer cited high-throughput Proteograph-Astral workflow as support for population-scale biomarker discovery and drug-target research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686692) on April 09, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626518490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 20:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626518490","market":"us","top_or_hot":-1,"title":"Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Seer Proteograph Product Suite selected to profile plasma proteome in 10,000 PRECISE-SG100K participants under collaboration with Precision Health Research, Singapore.\n        </li>\n<li>\n          Project combines Proteograph data with Thermo Fisher Olink Reveal and Orbitrap Astral outputs from same samples to expand proteomic readouts.\n        </li>\n<li>\n          Seer cited high-throughput Proteograph-Astral workflow as support for population-scale biomarker discovery and drug-target research.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686692) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-09 20:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Seer Proteograph Product Suite selected to profile plasma proteome in 10,000 PRECISE-SG100K participants under collaboration with Precision Health Research, Singapore.\n        </li>\n<li>\n          Project combines Proteograph data with Thermo Fisher Olink Reveal and Orbitrap Astral outputs from same samples to expand proteomic readouts.\n        </li>\n<li>\n          Seer cited high-throughput Proteograph-Astral workflow as support for population-scale biomarker discovery and drug-target research.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686692) on April 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014005.SGD","symbol_name":"United Global Durable Equities Fund Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL87JPhQ:1","article_id":"2626518490","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626518490","pubTimestamp":1775736598,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Seer Proteograph Product Suite selected to profile plasma proteome in 10,000 PRECISE-SG100K participants under collaboration with Precision Health Research, Singapore.Project combines Proteograph data with Thermo Fisher Olink Reveal and Orbitrap Astral outputs from same samples to expand proteomic readouts.Seer cited high-throughput Proteograph-Astral workflow as support for population-scale biomarker discovery and drug-target research.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","NDAQ":"纳斯达克OMX交易所","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","LU2041044095.USD":"Blackrock Circular Economy A2 USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU1803068623.USD":"TEMPLETON GLOBAL CLIMATE CHANGE \"AH1\" (USDHDG) ACC","BK4121":"生命科学工具和服务","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4581":"高盛持仓","LU2125909759.SGD":"Natixis Thematics Safety H-R/A SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2125909916.SGD":"Natixis Thematics Safety R/A SGD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","BK4534":"瑞士信贷持仓","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU1923622291.USD":"Natixis Thematics Safety R/A USD","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","SEER":"Seer, Inc.","BK4535":"淡马锡持仓","TMO":"赛默飞世尔","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2360108059.USD":"BGF CIRCULAR ECONOMY \"A4\" (USD) INC","BK4588":"碎股","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0061474960.USD":"天利环球焦点基金AU Acc","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"选择Seer蛋白图用于10,000份PRECISE-SG100K样品的血浆蛋白质组学分析","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"SEER":0.9,"TMO":0.9},"content_text":"Seer Proteograph selected for plasma proteomics profiling of 10,000 PRECISE-SG100K samples\n    \n\n\n          Seer Proteograph Product Suite selected to profile plasma proteome in 10,000 PRECISE-SG100K participants under collaboration with Precision Health Research, Singapore.\n        \n\n          Project combines Proteograph data with Thermo Fisher Olink Reveal and Orbitrap Astral outputs from same samples to expand proteomic readouts.\n        \n\n          Seer cited high-throughput Proteograph-Astral workflow as support for population-scale biomarker discovery and drug-target research.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seer Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604090800PRIMZONEFULLFEED9686692) on April 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626518490","isCrawlerRequest":true}